Wiese, W.;                     Siwecka, N.;                     Wawrzynkiewicz, A.;                     Rozpędek-Kamińska, W.;                     Kucharska, E.;                     Majsterek, I.    
        IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers 2022, 14, 2526.
    https://doi.org/10.3390/cancers14102526
    AMA Style
    
                                Wiese W,                                 Siwecka N,                                 Wawrzynkiewicz A,                                 Rozpędek-Kamińska W,                                 Kucharska E,                                 Majsterek I.        
                IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers. 2022; 14(10):2526.
        https://doi.org/10.3390/cancers14102526
    
    Chicago/Turabian Style
    
                                Wiese, Wojciech,                                 Natalia Siwecka,                                 Adam Wawrzynkiewicz,                                 Wioletta Rozpędek-Kamińska,                                 Ewa Kucharska,                                 and Ireneusz Majsterek.        
                2022. "IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies" Cancers 14, no. 10: 2526.
        https://doi.org/10.3390/cancers14102526
    
    APA Style
    
                                Wiese, W.,                                 Siwecka, N.,                                 Wawrzynkiewicz, A.,                                 Rozpędek-Kamińska, W.,                                 Kucharska, E.,                                 & Majsterek, I.        
        
        (2022). IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers, 14(10), 2526.
        https://doi.org/10.3390/cancers14102526